TAK-418

CAS No. 1818252-53-7

TAK-418( —— )

Catalog No. M35103 CAS No. 1818252-53-7

TAK-418 is a selective and orally active inhibitor of LSD1/KDM1A enzyme with an IC50 of 2.9 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 387 In Stock
5MG 330 In Stock
10MG 521 In Stock
25MG 1064 In Stock
50MG 1404 In Stock
100MG 1879 In Stock
200MG 2539 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    TAK-418
  • Note
    Research use only, not for human use.
  • Brief Description
    TAK-418 is a selective and orally active inhibitor of LSD1/KDM1A enzyme with an IC50 of 2.9 nM.
  • Description
    TAK-418 is a selective, orally active LSD1 (KDM1A) enzyme inhibitor with an IC50 of 2.9 nM. TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    Histone Demethylase
  • Recptor
    Histone Demethylase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1818252-53-7
  • Formula Weight
    356.91
  • Molecular Formula
    C17H25ClN2O2S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 55 mg/mL (154.10 mM; Ultrasonic (<60°C); )H2O : ≥ 16.67 mg/mL (46.71 mM)
  • SMILES
    Cl.O=C(NC1CCOCC1)c1csc(c1)[C@@H]1C[C@H]1NCC1CC1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Baba R, et al. LSD1 enzyme inhibitor TAK-418 unlocks aberrant epigenetic machinery and improves autism symptoms in neurodevelopmental disorder models. Sci Adv. 2021;7(11):eaba1187. Published 2021 Mar 12.?
molnova catalog
related products
  • MRTX9768

    MRTX-9768 is a synthetic lethal-based inhibitor designed to bind the PRMT5-MTA complex and selectively target MTAP/CDKN2A-deleted tumors.

  • M?89

    M-89 inhibits the menin-mixed lineage leukemia (Menin-MLL) protein-protein interaction and has potential to treat MLL leukemia.?M-89 is a highly potent and specific menin inhibitor, with a Kd of 1.4 nM for binding to menin.

  • SD49-7

    SD49-7 is an inhibitor of histone lysine demethylase 4 (KDM4) with an IC50 of 0.19 μM.